Aspirin plays a critical role in preventing serious complications after heart attacks and stent placements. It’s a core component of dual antiplatelet therapy (DAPT), usually paired with medications like clopidogrel or ticagrelor. However, around 2.5% of the population is hypersensitive to aspirin, creating a dilemma: how to protect these patients from blood clots without the most effective drug available?

Aspirin hypersensitivity can take many forms — from mild rashes and nasal congestion to life-threatening anaphylaxis or severe asthma attacks. These reactions may be pharmacological, caused by a shift in inflammatory pathways, or immunological, triggered by the body’s immune response. Despite its risks, no alternative to aspirin has been proven equally effective in the critical period following percutaneous coronary intervention (PCI) or myocardial infarction (MI). Read More >